Sionna Therapeutics showcases novel CFTR stabilizers at NACFC 2023
At the forefront of cystic fibrosis research, Sionna Therapeutics recently unveiled critical preclinical findings on their innovative Series 2 NBD1 stabilizers at the 2023 North ... Read More
Sage Therapeutics secures $3.1bn worth licensing deal for zuranolone and SAGE-217 with Biogen
Sage Therapeutics has secured a global collaboration and licensing deal worth up to $3.1 billion with Biogen for two of its drug candidates intended for ... Read More
ZULRESSO postpartum depression drug set to be launched in US by Sage Therapeutics
CNS biopharma company Sage Therapeutics is all set to commercially launch its ZULRESSO (brexanolone) injection in the US later this month for the treatment of ... Read More